Butterfly Therapeutics (Previously Lucine)

📍 Laval, France👥 12 employees💰 Last funded Nov 2021
Pharmaceutical Manufacturing
LinkedIn
Lucine is part of Butterfly Therapeutics since december 2023. Lucine is an expert in women’s pelvic pain relief, and we’re on a mission to change women’s lives. We offer an evidence-based approach with scientifically proven solutions that reduce & relieve pain related to endometriosis, periods, menopause, post-partum discomfort, and more. Endocare is our clinically-tested, patented medical device that directly targets pain mechanisms with a unique combination of visual and sound frequencies Lets work together, changing womens lives !
4
Total investors
1
Early stage
2
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
4
Investor activity2018–2021 · investors recorded per year
201812020220211
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Butterfly Therapeutics (Previously Lucine)?
Butterfly Therapeutics (Previously Lucine) has 4 investors on record on gritt.io, including 1 early-stage backers, 2 mid-stage.
When did Butterfly Therapeutics (Previously Lucine) last raise funding?
The most recent investment in Butterfly Therapeutics (Previously Lucine) recorded on gritt.io was in November 2021.
What industry is Butterfly Therapeutics (Previously Lucine) in?
Butterfly Therapeutics (Previously Lucine) operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Butterfly Therapeutics (Previously Lucine) based?
Butterfly Therapeutics (Previously Lucine) is headquartered in Laval, France.